# SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer

> **NCT03645876** · PHASE2 · TERMINATED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 12 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** SHR-1210
- **DRUG:** BP102
- **DRUG:** oxaliplatin
- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT03645876
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-08
- **Primary completion:** 2019-04-18
- **Final completion:** 2019-04-18
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** The study was terminated early due to company decision
- **Last updated:** 2019-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03645876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03645876, "SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03645876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*